Trial Profile

A Phase Ib Study Evaluating the Safety and Efficacy of IBI188 in Combination With Demethylating Agents in Subjects With Acute Myeloid Leukemia

Status: Suspended

Phase of Trial: Phase I/II

Latest Information Update: 26 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Decitabine (Primary) ; Letaplimab (Primary)
Indications Acute myeloid leukaemia
Focus Therapeutic Use
Sponsors Innovent Biologics

Most Recent Events

20 Oct 2023 Planned End Date changed from 1 Jun 2024 to 31 Dec 2024.
20 Oct 2023 Planned primary completion date changed from 1 Jun 2023 to 30 Jun 2024.
14 Feb 2023 Number of treatment arms have been increased from 1 to 2 by the addition of Experimental: IBI188+decitabine arm, thus adding decitabine as a primary drug. Planned Patient enrollment has been increased.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com